Holen Sie sich die Stockscreener-App
4.61
0.43%
-0.02
Akari Therapeutics Plc Adr Aktie (AKTX) Neueste Nachrichten
Akari Therapeutics (NASDAQ: AKTX) registers 867,023 ADSs after ADS ratio change - Stock Titan
Akari Therapeutics PLC (FRA:CLA1) Stock Price, Trades & News - GuruFocus
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing Strategic Partnership with WuXi XDC - Sahm
Total equity of Akari Therapeutics Plc Sponsored ADR – LSX:A4270Y - TradingView — Track All Markets
Long term debt to total assets ratio of Akari Therapeutics Plc Sponsored ADR – FWB:CLA1 - TradingView
Discontinued operations of Akari Therapeutics Plc Sponsored ADR – MUN:CLA1 - TradingView
Akari Therapeutics partners with WuXi XDC on ADC development By Investing.com - Investing.com India
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing - Sahm
Who's Buying or Selling Akari Therapeutics PLC (FRA:CLA1) Stock Today? - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC (FRA:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics PLC Stock Baskets | FRA:CLA1 - GuruFocus
Akari Therapeutics PLC Stock Operating Data - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (FRA:CLA1) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Stock News, Headlines & Updates - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Valuation - GuruFocus
Akari Therapeutics PLC (STU:CLA1) Dividend - GuruFocus
Akari Therapeutics PLC Stock Baskets | STU:CLA1 - GuruFocus
Akari Therapeutics PLC (STU:CLA1)Valuation Measures & Financial Statistics - GuruFocus
Akari Therapeutics ADR: Dividend historical data and projections - marketscreener.com
Akari Therapeutics ADR: Revenue and Earnings Analysts Forecasts Revisions | AKTX | US00972G4055 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) sets ADS ratio to 1:80,000 in F-6/A filing - Stock Titan
Akari Therapeutics, Plc Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Akari Therapeutics (NASDAQ: AKTX) outlines ADC oncology strategy - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Declines By 19.4% - Defense World
Akari Therapeutics revises ADS ratio to maintain Nasdaq compliance - MSN
Get insights into the top gainers and losers of Thursday's after-hours session. - ChartMill
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 - ChartMill
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules By Investing.com - Investing.com India
Akari Therapeutics adjusts ADS ratio to meet Nasdaq rules - Investing.com South Africa
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Akari Therapeutics (NASDAQ: AKTX) plans 1-for-40 ADS ratio change to meet Nasdaq bid rules - Stock Titan
Director Neal James acquires Akari (AKTX) ADS warrants via placement and note swap - Stock Titan
Akari Therapeutics marks one year under CEO Gaslightwala By Investing.com - Investing.com India
Akari Therapeutics marks one year under CEO Gaslightwala - Investing.com
Akari Therapeutics (AKTX) investors approve multiple warrant exercisability resolutions - Stock Titan
Akari Therapeutics adds Dana-Farber expert to advisory board - Investing.com
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board - Finviz
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board - ChartMill
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference - Sahm
Will Akari Therapeutics Plc Depositary Receipt outperform the market in YEAR2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline - ChartMill
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Sahm
Akari Therapeutics (NASDAQ: AKTX) seeks approval for major warrant exercises - Stock Titan
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors - Sahm
Curious about the stocks that are showing activity after the closing bell on Monday? - Chartmill
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - GlobeNewswire Inc.
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 - Sahm
Akari Therapeutics to Present at the 2026 Biotech Showcase - Sahm
Why Vanda Pharmaceuticals Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Sahm
Akari Therapeutics Plc ADR (AKTX) Stock Sees a-0.57% Decrease - News Heater
Akari Therapeutics advances ADC oncology program with novel payload By Investing.com - Investing.com South Africa
Akari Therapeutics advances ADC oncology program with novel payload - Investing.com India
Operating cash flow per share of Akari Therapeutics Plc Sponsored ADR – FWB:CLA - TradingView — Track All Markets
AKTX SEC FilingsAkari Therapeutics Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Short Interest in Akari Therapeutics PLC (NASDAQ:AKTX) Expands By 650.6% - Defense World
Akari begins GMP manufacturing of lead ADC program with WuXi XDC - Investing.com
Akari begins GMP manufacturing of lead ADC program with WuXi XDC By Investing.com - Investing.com South Africa
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):